GSK3A and leukemia: While GSK3α is less studied in the context of Wnt signaling, recent work has shown that selective inhibition of GSK3α (e.g., BRD0705) can suppress leukemia initiation without promoting β-catenin stabilization, offering a potentially safer therapeutic avenue [146].